Clinical Trial: BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease

U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07729995) titled 'BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease' on July 15.

Brief Summary: Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory autoimmune disease, however not all disease responds or remains in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory autoimmune disease, even after relapse following other treatments. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against refractory autoimmune disease using a BAFF...